|Application ||WB, IHC-P, ICC, IP|
|Dilution||IHC-P (5 µg/ml), WB (2 µg/ml),|
|Other Names||Tumor protein p73, p53-like transcription factor, p53-related protein, TP73, P73|
|Target/Specificity||Full-length human p73. It reacts with an epitope that is located on the N-terminal region of human p73. It does not cross react with p53.|
|Reconstitution & Storage||Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles.|
|Precautions||TP73 / p73 Antibody (N-Terminus, clone 5B429) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.|
|Cellular Location||Nucleus. Cytoplasm. Note=Accumulates in the nucleus in response to DNA damage|
|Tissue Location||Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.
Kaghad M.,et al.Cell 90:809-819(1997).
Mai M.,et al.Genomics 51:359-363(1998).
De Laurenzi V.,et al.J. Exp. Med. 188:1763-1768(1998).
De Laurenzi V.,et al.Cell Death Differ. 6:389-390(1999).
Yoshikawa H.,et al.Oncogene 18:3415-3421(1999).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.